Not Yet RecruitingNot Applicable

A Two-armed Real-world Study of Ozempic (OW Semaglutide) to Evaluate Its Adherence and Persistence Compared With Other Anti-diabetic Drugs Among Adult T2DM Patients in China

China100,000 participantsStarted 2026-02-13

Plain-language summary

The study is testing the incidence of MACE and incidence of renal events between Ozempic® users and users with other anti-diabetic medications in T2D patients. This is a retrospective study, and participants had received Ozempic or any other anti-diabetic medications.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Participants had at least one prescription for Ozempic® or other interested anti-diabetic medications during the index identification period. * Participants had at least one diagnosis of T2D, and had at least one of the three following T2D clinical evidence any time before or on the index date * Participants had at least 1 all-cause visit record any time after 6 months post-index date. * At least 18 years old at the index date. Exclusion Criteria: * Patients who have used any same anti-diabetic medications as the index treatment within 6 months before index date (e.g., patient prescribed with any Ozempic® during baseline will be excluded if the index drug is a Ozempic®) * Patients with any diagnosis record of type 1 diabetes or gestational diabetes during whole study period. * Patients who were pregnant during the whole study period. * Patients who participated in any clinical trials during the whole study period. * Patients who were diagnosed with medullary thyroid carcinoma or multiple endocrine neoplasia type II (MEN2) during the whole study period.

What they're measuring

Time to 3P major adverse cardiovascular events

Timeframe: From index date to the first composite 3P MACE (stroke, myocardial infarction, all-cause death) event or censoring event (up to 36 months)

Time to 5P MACE

Timeframe: From index date to the first composite 5P MACE (stroke, myocardial infarction, all-cause death, heart failure hospitalization, coronary revascularization) event or censoring event (up to 36 months)

Time to stroke

Timeframe: From index date to the first stroke event or censoring event (up to 36 months)

Time to myocardial infarction (MI)

Timeframe: From index date to the first MI event or censoring event (up to 36 months)

Time to heart failure (HF)

Timeframe: From index date to the first HF event or censoring event (up to 36 months)

Time to composite renal event

Timeframe: From index date to first composite renal (kidney failure: dialysis/transplantation/eGFR <15, ≥50% eGFR reduction from baseline, or kidney-related/cardiovascular death) or censoring event (up to 36 months)

Time to renal disease-related hospitalization

Trial details

NCT IDNCT07456774

SponsorNovo Nordisk A/S

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2026-08-31

Contact for this trial

Novo Nordisk

(+1) 866-867-7178 clinicaltrials@novonordisk.com

View on ClinicalTrials.gov More Type 2 Diabetes trials